Piracetam Pharma Grade API, grade codes PIR-PG-101, PIR-PG-102, and PIR-PG-103, is the crystalline active pharmaceutical ingredient 2-oxo-1-pyrrolidine acetamide. The assigned grade codes designate the solid oral processing grade, the granulation-optimised grade, and the injectable grade, respectively. The compound has molecular formula C₆H₁₀N₂O₂, CAS 7491-74-9, and molecular weight 142.16 g/mol. It is a white or almost white crystalline powder with a melting range of 151–155 °C under the compendial capillary method. The substance is freely soluble in water and can be formulated as a 200 mg/mL injectable solution without cyclodextrin or surfactant solubilisation. Release testing follows the current European Pharmacopoeia monograph for piracetam, residual solvent limits under ICH Q3C(R8), elemental impurity limits under ICH Q3D, and manufacturing under ICH Q7 and EU GMP Part II. The product line is distributed with a certificate of analysis covering identity, assay, impurity, water, residual solvent, and particle-size parameters. Table 1 summarises the release profile for the solid oral and injectable grades.

Table 1. Release parameters for solid oral and injectable grades.

Pharmacopoeial alignment and control of crystalline purity

Compendial alignment is not limited to assay and infrared identity. Infrared absorption is performed according to Ph. Eur. 2.2.24 against a reference standard; a full spectrum match is required. Liquid chromatography uses an octadecylsilyl silica column with dimensions 150 mm × 4.6 mm and 5 µm particle size. System suitability requires resolution between piracetam and the nearest specified impurity of ≥2.0 and tailing factor ≤2.0. Unspecified impurity acceptance is ≤0.10%, and total impurities are ≤0.5%. The crystal lattice is controlled by X-ray powder diffraction; the anhydrous form is confirmed and no hydrate transition is accepted. Residual solvents are measured by headspace gas chromatography against ICH Q3C(R8) limits. Class 3 solvents are controlled at ≤0.5% each. Elemental impurities are assessed by inductively coupled plasma mass spectrometry under ICH Q3D Option 1. Residual pyrrolidine, where applicable, is controlled by gas chromatography with flame ionisation at ≤0.1%. These controls are batch-to-batch release specifications, not development data.

The injectable grade is not interchangeable with the solid oral grade. PIR-PG-103 carries additional control of bacterial endotoxins at ≤0.5 EU/g and bioburden at TAMC ≤100 CFU/g, TYMC ≤10 CFU/g. Endotoxin control is achieved by depyrogenation of crystallisation water and by validated cleaning of the centrifuge, dryer, and milling equipment. An oral-grade lot can meet pharmacopoeial related substances limits and still fail injectable endotoxin criteria; substitution is not acceptable under GMP batch disposition.

In solid oral manufacture, the API is typically incorporated at 800 mg or 1,200 mg per unit, producing a high drug-to-excipient ratio. Wet granulation with PIR-PG-102 is performed in a high-shear granulator with bowl temperature 25–35 °C, impeller speed 200–400 rpm, and chopper speed 1,500–3,000 rpm. Purified water or an aqueous binder solution is added at 0.8–1.2 mm/min per kilogram of dry mass. Granulation end point is controlled by impeller torque and moisture content; overdense granules result in excessive fines after milling and capping during compression. The wet mass is dried in a fluid-bed dryer at inlet temperature 50–60 °C to loss on drying 1.0–2.0%. Dried granules are milled through a cone mill with a 0.5 mm screen at 1,500 rpm. Direct compression with PIR-PG-101 is feasible only when the API fraction is below 70% w/w; above this fraction, capping has been observed at compression force above 18 kN. Roller compaction at roll pressure 4–8 MPa and screen size 1.0–1.5 mm is the preferred densification route for direct compression formulations.

Capsule filling is performed on a tamping pin or dosator machine. A 400 mg piracetam capsule typically requires total fill mass 420–460 mg depending on excipient density. The Hausner ratio of the final blend is maintained below 1.25 to avoid weight variation exceeding ±5% at 60,000 capsules/h. Lubrication with magnesium stearate is limited to 0.5–1.0% w/w for 3–5 minutes; over-lubrication increases disintegration time and slows dissolution in USP <711> testing. High-dose tablet cores are compressed on rotary presses with capsule-shaped punches from 19 mm × 8 mm to 21 mm × 9 mm. Tablet hardness is maintained at 80–120 N, friability at ≤1.0% under USP <1216>, and disintegration at ≤15 min under USP <701> for uncoated immediate-release cores.

The grade code PIR-PG-101 is assigned to the solid oral powder, PIR-PG-102 is the granulation-optimised grade with slightly lower D50, and PIR-PG-103 is the injectable grade with additional endotoxin and bioburden release. All grades are supplied with a certificate of analysis, certificate of conformance, and residual solvent declaration. For EU submissions, a certificate of suitability may be available; for US filings, the manufacturing lot is supported by a Type II drug master file reference. These documentation differences are operational rather than pharmacological; the active moiety is unchanged across grades.

How does particle size distribution affect tablet compression and injection clarity?

Particle-size distribution exerts a dual effect. In solid oral processing, a D90 above 250 µm increases segregation risk in low-dose blends, while a D10 below 10 µm increases dust generation and may require local exhaust ventilation. The solid oral grade PIR-PG-101 is milled to D10 20–40 µm, D50 80–120 µm, and D90 ≤250 µm. PIR-PG-102 for aqueous granulation is controlled to D50 60–80 µm to favour wetting and uniform binder distribution. Laser diffraction is performed under Mie theory with obscuration 10–15%; the refractive index setting is qualified against the compendial standard and equipment vendor specifications.

In injectable processing, piracetam is dissolved rather than suspended, so particle size is not the primary clarity determinant. Subvisible particulate burden in the final solution is governed by filter compatibility, filling environment, and stopper shedding. Final solution is tested under USP <788> with limits of ≥10 µm particles ≤6,000 per container and ≥25 µm particles ≤600 per container. PIR-PG-103 is released with a clear solution test: a 200 mg/mL solution in Water for Injection filtered through 0.22 µm polyethersulfone must show no visible particles and must meet spectrophotometric absorbance at 400 nm ≤0.10 AU. Dissolution rate in solid oral forms is less particle-size-sensitive than in poorly soluble drugs because piracetam is freely soluble; USP <711> single-point dissolution testing for immediate-release tablets is typically met before the 15-minute sampling point. Published dissolution data specific to this particle-size grade are limited, and site-specific method validation is required.

When terminal moist-heat sterilization is selected for piracetam injection

When terminal moist-heat sterilization is selected for a 200 mg/mL piracetam solution, the critical variables are pH, oxygen, and stopper/silicon contact. The solution pH is adjusted to 5.5–6.5 with 0.1 M hydrochloric acid or sodium hydroxide; this range minimises hydrolytic ring opening while maintaining tonicity equivalent to 0.9% sodium chloride. The filled vials are autoclaved at 121 °C for 15 minutes, corresponding to a minimum F0 of 8. Pre-sterilisation bioburden is controlled at ≤10 CFU/100 mL to meet a sterility assurance level of 10^-6 under terminal sterilisation. Aseptic filtration through 0.22 µm polyethersulfone membrane may be used as pre-filtration before autoclaving; the terminal cycle remains the defined sterilisation step.

The API PIR-PG-103 is specified with low endotoxin and bioburden as described above. It is incompatible with strong oxidising agents and should not be exposed to direct sunlight for extended periods. Aqueous solutions should be stored in Type I borosilicate glass vials with bromobutyl rubber stoppers; polyvinyl chloride bags are acceptable for short-term admixture only when leachate data support the proposed contact time. Published stability data for prolonged storage of piracetam admixtures in flexible polyolefin containers is limited, and site-specific stability is required before use. Filter validation is performed at 200 mg/mL because piracetam is hydrophilic; polyethersulfone and nylon filters generally show <5% drug loss per 100 mL in laboratory spiking studies, but production filter compatibility must be confirmed with the selected filter lot and filling line.

The Difference From Non-GMP Nootropic Powders Lies in Residual Control

Non-pharmacopoeial piracetam powders are often certified only for appearance, melting point, and assay. That documentation does not establish compliance with ICH Q7, does not include residual solvent certification against ICH Q3C(R8), and omits elemental impurity data under ICH Q3D. Those materials are not manufactured under a current EU GMP Part II quality system and should not be used in tablet, capsule, granule, or injectable manufacturing. This product line is released with a pharmacopoeial impurity profile, residual solvent profile, and, for parenteral grade, endotoxin and bioburden testing. The residual control difference is the primary regulatory boundary: a non-GMP lot can pass a simple melting-point test and still fail pharmacopoeial related substances or injectable endotoxin criteria.

Compared with lipophilic racetam APIs, piracetam has the lowest molecular weight and highest aqueous solubility. Aniracetam has a molecular weight of 219.24 g/mol and is practically insoluble in water, requiring lipid or high-surfactant formulation. Oxiracetam has a molecular weight of 158.16 g/mol and is water soluble but introduces a hydroxy-substituted pyrrolidinone ring that alters chromatographic retention and moisture uptake. Piracetam is suitable for injectable application because the unmodified 2-oxo-1-pyrrolidine acetamide structure supports terminal sterilisation and aqueous solubility at 200 mg/mL without cyclodextrin. For solid oral forms, the absence of an ester or hydroxy substituent reduces hydrolytic instability; piracetam tablets and capsules are therefore less sensitive to moisture-induced degradation during storage than esterified racetams. The selection of piracetam over alternative racetams depends on dose, route, and compendial status in the target market.

Because piracetam is a compendial active substance in the European Pharmacopoeia and other pharmacopoeias, regulatory acceptance in multiple markets is direct. Non-compendial racetam APIs may not have harmonised monographs, requiring additional method and stability validation before formulation. The operational difference is therefore not pharmacological potency but control of manufacturing impurities, physical grade, and documentation that permits use in oral and injectable dosage forms.